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Abstract Apoptosis in the heart can be triggered by ischemia
and/or reperfusion depending on conditions. This may involve
activation of plasma membrane death receptors and/or trans-
location of Bcl-2 homologous proteins to mitochondria. How-
ever, one of the main mechanisms for triggering this apoptosis
appears to be mitochondrial permeability transition followed by
cytochrome c release. Cytochrome c release can result in cas-
pase activation and thus apoptosis, but also results in mitochon-
drial dysfunction, which might contribute to contractile dysfunc-
tion or necrosis at reperfusion.
 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Apoptosis is a highly regulated form of cell death, essential
to the normal development of an organism, and designed to
eliminate unwanted cells. However, excessive apoptosis may
contribute to pathological processes. The mechanisms of ap-
optotic cell death have been well studied in various non-my-
ocytic cells and cell lines. In contrast, terminally di¡erentiated
cardiomyocytes have been considered to die exclusively by
necrosis. Accumulating evidence indicates that cardiomyocyte
apoptosis does occur in di¡erent cardiac diseases such as is-
chemic heart disease, heart failure and aging. Ischemia/reper-
fusion-induced cardiomyocyte apoptosis has been shown both
in animals [1^4] and in humans [5^7].
There are a variety of endogenous inhibitors of apoptosis,
some of which are exclusively expressed in myogenic cells (e.g.
apoptosis repressor with caspase recruitment domain (ARC))
[8]. For example, IAP (inhibitor of apoptosis proteins), FLIP
(FADD-like inhibitory proteins), some heat shock proteins
and ARC inhibit apoptosis by binding and inhibiting cas-
pases. The abundance of ARC and other inhibitory proteins
in myocytes may be one possible explanation why apoptosis
though present in ischemic/reperfused heart usually is not ex-
tensive (just a few percent of the total number of cardiomyo-
cytes) compared to necrotic cell death [8]. However, in some
conditions apoptosis is greater and even more abundant than
necrosis [9,10]. Furthermore, apoptosis or its underlying
mechanism ^ caspase activation ^ may subsequently cause
necrosis, so that caspase inhibitors have been shown to reduce
infarct size after ischemia [11,12].
Induction of apoptosis in ischemic/reperfused hearts has
been suggested to be mediated by a variety of pathways which
may or may not be interrelated, including: (a) activation of
Fas or tumor necrosis factor-K (TNFK) receptors; (b) activa-
tion of p53 and c-Jun kinase pathways; (c) downregulation of
antiapoptotic Bcl-2 protein and upregulation of proapoptotic
Bax protein; (d) in¢ltration and activation of neutrophils and/
or macrophages (reviewed in [13,14]). These pathways are
more likely to be involved during reperfusion, whereas ische-
mia itself may initiate apoptosis via a mitochondrial pathway.
Mitochondria play several roles in apoptosis : (a) they supply
ATP that is necessary for execution of apoptosis ; (b) they
release cytochrome c and apoptosis-inducing factor proteins
that are involved in caspase activation and nuclear fragmen-
tation; (c) they release proteins (second mitochondria-derived
activator of caspases SMAC/DIABLO) that neutralize endog-
enous inhibitors of apoptosis. In this short review we highlight
the role of the mitochondrial pathway of apoptosis in ische-
mic heart and consider the consequences of mitochondrial
cytochrome c loss.
2. When does apoptosis occur ^ during ischemia or reperfusion?
Previous published ¢ndings have been contradictory as to
whether apoptosis is induced during ischemia or reperfusion.
Apoptosis as an early and predominant form of cell death has
been detected in human acute myocardial infarcts and it was
shown to increase in reperfused myocardium [7]. In various
animal models of ischemia/reperfusion it was shown that pro-
longed (6^7 h) ischemia causes no signi¢cant apoptosis but it
is greatly accelerated by reperfusion [1,4,13]. Other investiga-
tors [2,3] found the ¢rst signs of apoptosis as early as after 10
min ischemia reaching maximum levels at 30^60 min ischemia
with further increase [2] or no change [3] at reperfusion. Our
own studies showed that caspase activation is already detect-
able after 30 min ischemia with DNA fragmentation at 60 min
ischemia of isolated rat heart, and both parameters increased
during reperfusion [15,16]. The reasons for these contradictory
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¢ndings are unclear, but may relate to the degree of anoxia in
di¡erent models of ischemia, age of experimental animals or
species speci¢cities. There may be several phases of apoptosis
following reperfusion, including an initial phase following
rapidly after reperfusion, an intermediate phase following
neutrophil in¢ltration into the heart, and a delayed phase
days, weeks or months after the insult that may be involved
in remodeling and heart failure [13]. Ischemia itself may vary
in severity, ranging from acute total ischemia to chronic par-
tial ischemia. The mechanisms of cell death involved in all
these di¡erent phases and conditions are unlikely to be the
same.
3. Which pathway causes caspase activation after ischemia?
Several of the morphological features of apoptosis are
caused by caspase activity, and activation of caspases is often
considered a key biochemical hallmark of apoptosis. Caspases
are specialized cysteine-dependent proteases that cleave major
structural proteins of the cytoplasm and nucleus [17]. In nor-
Fig. 1. Three pathways of caspase activation. In the receptor pathway, caspase-8 is recruited to a death receptor at the plasma membrane and
then undergoes self-cleavage. The activated caspase-8 can then proteolytically activate caspase-3. Mitochondria release cytochrome c, which
binds to the cytosolic protein Apaf-1 and facilitates activation of caspase-9. ER stress causes activation of caspase-12, which can activate cas-
pase-9. There is cross-talk between the pathways, as caspase-8 can cleave cytosolic Bid, which can then bind to mitochondria and induce the re-
lease of cytochrome c.
Fig. 2. Mitochondrial mechanisms of cell dysfunction and death in ischemic myocardium. Ischemia causes MPT-related cytochrome c release,
which then induces caspase activation and apoptosis. Caspase activation may feedback to cause further cytochrome c release, and cytochrome c
release is partially responsible for mitochondrial dysfunction, which might lead to contractile dysfunction or necrosis at reperfusion.
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mal healthy cells caspases are present as poorly active or in-
active zymogens that can be activated by autocleavage or pro-
cessing by other proteases. To date three main pathways of
caspase activation have been described (Fig. 1). The ¢rst path-
way is initiated by binding of extracellular ligands (Fas ligand,
TNFK) to their cell surface receptors leading to caspase-8
activation [18]. The second is mediated by mitochondria,
which release apoptogenic proteins, mainly cytochrome c. Cy-
tochrome c once released into the cytosol binds to a cytosolic
protein apoptotic protease-activating factor (Apaf-1) and this
complex in the presence of dATP or ATP facilitates activation
of caspase-9, which in turn activates downstream caspase-3
[19,20]. The third pathway is initiated by endoplasmic retic-
ulum (ER) stress (due to depletion of ER calcium or accumu-
lation of unfolded proteins) and causes activation of caspase-
12 [21], which recently has been shown to activate caspase-9
[22]. It remains unclear whether this pathway may operate in
human cells because a human homologue of murine caspase-
12 has not been found.
In principle, one or more of these pathways might be in-
duced in ischemic/reperfused heart. Cardiomyocytes have Fas
and TNFK receptors, and heart cells are known to produce
Fas ligand and TNFK, which may activate the death receptor-
mediated pathway [23,24]. Fas and TNFK have been impli-
cated in late apoptosis after reperfusion: mice lacking func-
tional Fas have reduced apoptosis 24 h after 30 min ischemia
[25]. However, Fas and TNFK have not been implicated in
apoptosis induced by hypoxia alone. During ischemia/reper-
fusion, there is also an increase in intracellular Ca2þ [26],
which may lead to mitochondrial permeability transition
(MPT) or ER stress. However, there is as yet no evidence
that caspase-12 or ER stress is involved in apoptosis induced
by heart ischemia/reperfusion.
In contrast to the other two potential pathways of caspase
activation, there is strong evidence that the mitochondrial
cytochrome c pathway participates in apoptosis induced by
heart ischemia. Cytochrome c is released from mitochondria
after 30^60 min of heart ischemia [15,16,27,28] ; agents block-
ing cytochrome c release block apoptosis [16] ; and addition of
exogenous cytochrome c to heart cytosol (plus dATP) is suf-
¢cient to activate caspases to a similar extent as apoptosis
[15].
4. What is the mechanisms of mitochondrial cytochrome c
release?
Two mechanisms of cytochrome c release from mitochon-
dria have been described. The ¢rst mechanism involves for-
mation of a large channel in the outer mitochondrial mem-
brane, due to oligomerization of certain Bcl-2 homologous
proteins such as Bax or Bak. Bax is normally present as a
monomer in the cytosol of many cells, including cardiomyo-
cytes, but translocates to mitochondria and oligomerizes to
form a pore in response to the translocation of Bcl-2 homol-
ogous domain-2 (BH3)-only proteins such as Bid, Bad and
Bim [29^31]. Bak is normally present in mitochondria; Bax,
Bid and Bad are cytosolic proteins but they translocate to
mitochondria when apoptosis is induced [30,32]. Bid can be
cleaved by caspase-8 and calpains, and then truncated Bid
translocates to mitochondria causing cytochrome c release
[31,33]. Bad can be dephosphorylated by calcium-dependent
phosphatase calcineurin and then it translocates to mitochon-
dria [34]. Recently a new Bcl-2 homologue, BNIP3, was found
to be induced in cardiomyocytes by chronic hypoxia, while
simultaneous acidosis was required for BNIP3 translocation
to mitochondria and subsequent apoptosis, which appear to
involve MPT but not caspases [35].
The second mechanism for cytochrome c release from mi-
tochondria is mediated by opening of the MPT pore. MPT is
a dramatic increase in permeability of the inner mitochondrial
membrane to small (up to 1.5 kDa) molecules (for reviews see
[36^38]). The MPT pore is formed at the site of contact be-
tween mitochondrial inner and outer membranes, and may
consist of cyclophilin D, adenine nucleotide translocator, mi-
tochondrial voltage-dependent anion channel (VDAC, also
called porin), creatine kinase and possibly other proteins
[36^38]. MPT can be induced by high calcium or oxidative
stress especially when this is accompanied by depletion of
adenine nucleotides, increase in phosphate levels and decrease
in mitochondrial membrane potential, i.e. conditions present
during heart ischemia and reperfusion. How MPT causes cy-
tochrome c release is not clear yet. MPT causes mitochondrial
swelling which may result in rupture of the mitochondrial
outer membrane. However, mitochondrial swelling does not
always occur in apoptotic cells, and studies on isolated heart
or brain mitochondria have shown that release of cytochrome
c can be induced by calcium or other MPT inducers without
swelling [39,40]. BH3 proteins may also be involved in MPT
pore formation. Bax-induced cytochrome c release in some
cells or isolated mitochondria has been shown to be partially
sensitive to cyclosporin A, suggesting involvement of MPT
[41]. Bax, Bak and Bim have been shown to directly interact
with VDAC and to induce cytochrome c release by accelerat-
ing opening of VDAC [42]. However, truncated Bid, Bim or
Bax can cause cytochrome c release independently from MPT
[43], probably by directly forming pores in the membrane
phospholipid bilayers [44].
5. Does MPT occur during ischemia?
The most common approach to demonstrate the involve-
ment of MPT in cell death is the use of cyclosporin A as a
speci¢c inhibitor of MPT. However, this must be taken with
some caution because cyclosporin A also inhibits calcineurin,
a calcium-dependent phosphatase, which besides many other
roles in the cells can cause dephosphorylation of Bad and its
translocation to mitochondria causing cytochrome c release.
Using cyclosporin A MPT has been implicated in ischemia
and reperfusion-induced damage to isolated hearts [45^48],
or loss of heart tissue viability due to depletion of mitochon-
drial and cytosolic NADþ during reperfusion [49]. These stud-
ies concluded that MPT occurs during reperfusion rather than
during ischemia itself. However, another study showed that
cyclosporin protects from progression of cell injury during
substrate-free anoxia of isolated cardiomyocytes [45], suggest-
ing that MPT could occur during ischemia. Also, our own
work showed that cyclosporin A but not the calcineurin in-
hibitor FK506 prevented ischemia-induced cytochrome c re-
lease from mitochondria, mitochondrial dysfunction, caspase
activation and nuclear fragmentation in perfused rat heart
[16].
Gri⁄ths and Halestrap [47] developed a more direct meth-
od of measurement of MPT by perfusing hearts with 2-de-
oxy[3H]glucose and then measuring how much had penetrated
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into subsequently isolated mitochondria. They found that the
label did not penetrate into mitochondria during ischemia, but
did after reperfusion, suggesting that MPT occurred only at
reperfusion. However, the interpretation of these experiments
is complex, as it was found that perfusion of the hearts with
cyclosporin A prior to ischemia did not decrease radiolabel
uptake but rather increased it. The same study found that 30
min ischemia caused the yield (measured by citrate synthase
activity) of subsequently isolated mitochondria to decrease by
33%, and this large loss of mitochondria was prevented by
perfusion with cyclosporin A. This suggests that ischemia
without reperfusion causes MPT-mediated damage to a pro-
portion of the mitochondria, which may include damage to
the inner membrane such that the radiolabel cannot be re-
tained. Thus, it would appear that under some conditions
MPT can occur during both ischemia and reperfusion.
The factors triggering MPT during ischemia/reperfusion are
unclear, but have been suggested to include increased reactive
oxygen/nitrogen species, calcium, phosphate, free fatty acids
or decreased adenine nucleotides and mitochondrial mem-
brane potential (reviewed in [37,38]).
6. What are the consequences of mitochondrial cytochrome c
release during heart ischemia?
Cytochrome c release during heart ischemia may have a
number of consequences: (1) caspase activation, (2) inactiva-
tion of the mitochondrial respiratory chain, and (3) mitochon-
drial free radical production. The cytochrome c release may
have little or no consequence if the heart stays ischemic, as the
ATP depletion will limit caspase activation and cause wide-
spread necrosis. But if the heart is reperfused, the cytochrome
c release and caspase activation that occurred during the pre-
vious ischemic period will trigger further caspase activation at
reperfusion, potentially causing widespread apoptosis. This is
consistent with our own and others’ ¢ndings that reperfusion
stimulates further caspase activation [16,50].
Release of cytochrome c from mitochondria inactivates mi-
tochondrial respiration as cytochrome c is an essential com-
ponent of the respiratory chain. Mitochondria isolated from
ischemic heart have a severely inhibited respiratory chain,
resulting in inhibited respiration and ATP synthesis [26,28,
51]. And this inactivation of the respiratory chain, at least
with short-term ischemia (30 min), is largely due to the loss
of cytochrome c, as the inhibition can be reversed by simply
adding cytochrome c to the isolated mitochondria [28]. With
longer-term ischemia (45^60 min) mitochondrial dysfunction
is also due to inhibition of complex I and the adenine nu-
cleotide carrier, and due to uncoupling by fatty acids [26,
28,52,53]. At reperfusion the inhibition of mitochondrial res-
piration and ATP synthesis resulting from ischemia may po-
tentially contribute to the known contractile dysfunction, and
necrosis. There is no direct evidence for this, but it is known
that ischemia severely inhibits the respiratory chain, and that
speci¢c respiratory inhibitors can cause rapid contractile dys-
function and necrosis [26].
Loss of mitochondrial cytochrome c may potentiate mito-
chondrial production of oxidants at reperfusion, because (a)
cytochrome c is a catalytic scavenger for mitochondrial super-
oxide, and (b) loss of cytochrome c results in reduction of
complexes I, II and III potentiating superoxide production
[54,55]. Thus loss of cytochrome c may contribute to the
known burst of oxidant production when oxygen is returned
at reperfusion. However, there is no direct evidence for ische-
mic loss of cytochrome c being responsible for the oxidant
burst at reperfusion.
Note if MPT occurs during ischemia this will also promote
necrosis by causing ATP depletion, via allowing ATP directly
into the matrix and ATP hydrolysis by reversal of the ATP
synthase.
7. Conclusions
Heart apoptosis can be triggered by ischemia and/or reper-
fusion depending on conditions. One of the main mechanisms
for triggering this apoptosis appears to be MPT followed by
cytochrome c release. Cytochrome c release can result in cas-
pase activation and thus apoptosis, but also results in mito-
chondrial dysfunction, which might contribute to contractile
dysfunction or necrosis at reperfusion (Fig. 2).
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